南模生物董事会再现分歧：费俭继续担任董事长，总经理王明俊被替换

Core Viewpoint - The internal conflicts within the board of directors of Nanmo Biology have drawn significant attention from the capital market, particularly following the recent management changes and the ongoing disagreements among board members [1][4]. Group 1: Management Changes - Nanmo Biology announced the re-election of Fei Jian as chairman and the appointment of Zhang Chunming as general manager and CFO, marking a significant shift in the company's core management [1][3]. - The board's recent meetings revealed multiple dissenting and abstaining votes regarding the election of committee members and the appointment of the new general manager, indicating persistent internal divisions [2][3]. Group 2: Board Dynamics - The newly formed board committees are led by members nominated by major shareholders, with Fei Jian holding significant influence over strategic decisions [2]. - The absence of former general manager Wang Mingjun from the committee member list suggests a decline in his influence within the company, as he opposed several key proposals during the board meetings [2][3]. Group 3: Historical Context - Fei Jian and Wang Mingjun, once aligned as partners, have recently experienced a breakdown in their collaborative relationship, which has become evident in board decisions and strategic discussions [3][4]. - The dissolution of their previously unified action agreement has led to increased conflicts during board elections and strategic planning, raising concerns about the stability of control within Nanmo Biology [4]. Group 4: Financial Performance - Nanmo Biology has shown revenue growth, with a reported revenue of 196 million yuan in the first half of the year, reflecting a year-on-year increase of 10.69%, while the net profit attributable to shareholders rose by 298.69% to 18.17 million yuan [5]. - Despite the revenue growth, the company has faced challenges with profitability, as indicated by negative net profits for three consecutive years from 2022 to 2024 [5].